TY  -  
T1  - Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma 
SN  -  /  
UR  - http://hdl.handle.net/10138/338049 
T3  -  
A1  - Matasar, Matthew J.; Dreyling, Martin; Leppä, Sirpa; Santoro, Armando; Pedersen, Michael; Buvaylo, Viktoriya; Fletcher, Monique; Childs, Barrett H.; Zinzani, Pier Luigi 
A2  -  
PB  -  
Y1  - 2021 
LA  - eng 
AB  - Combining oral PI3K inhibitors with immunochemotherapy for indolent B-cell lymphoma has been associated with toxicity. In the Phase III CHRONOS-4 safety run-in, 21 patients received intravenous copanlisib plus rituximab-based immunochemotherapy. There were no dose-limiting toxicities, and preliminary objective response rates were 90% to 100%. Copanlisib is the first PI3K inhibitor to demonstrate safe, tolerable, and effective combinability with immunochemotherapy, with evaluation ongoing. Backgr... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - Bendamustine; CHRONOS-4; Phase III; R-CHOP; Safety run-in; NON-HODGKIN-LYMPHOMA; RESPONSE ASSESSMENT; PI3K INHIBITORS; DOSE-ESCALATION; PHASE-I; MALIGNANCIES; 3122 Cancers 
N1  -   
PP  -  
ER  -